Schaller Sophie, Henriksen Kim, Sveigaard Christina, Heegaard Anne-Marie, Hélix Nathalie, Stahlhut Martin, Ovejero Maria C, Johansen Jens V, Solberg Helene, Andersen Thomas L, Hougaard Dorit, Berryman Mark, Shiødt Christine B, Sørensen Bjørn H, Lichtenberg Jens, Christophersen Palle, Foged Niels T, Delaissé Jean-Marie, Engsig Michael T, Karsdal Morten A
Nordic Bioscience A/S, Herlev, Denmark.
J Bone Miner Res. 2004 Jul;19(7):1144-53. doi: 10.1359/JBMR.040302. Epub 2004 Mar 1.
Chloride channel activity is essential for osteoclast function. Consequently, inhibition of the osteoclastic chloride channel should prevent bone resorption. Accordingly, we tested a chloride channel inhibitor on bone turnover and found that it inhibits bone resorption without affecting bone formation. This study indicates that chloride channel inhibitors are highly promising for treatment of osteoporosis.
The chloride channel inhibitor, NS3736, blocked osteoclastic acidification and resorption in vitro with an IC50 value of 30 microM. When tested in the rat ovariectomy model for osteoporosis, daily treatment with 30 mg/kg orally protected bone strength and BMD by approximately 50% 6 weeks after surgery. Most interestingly, bone formation assessed by osteocalcin, mineral apposition rate, and mineralized surface index was not inhibited.
Analysis of chloride channels in human osteoclasts revealed that ClC-7 and CLIC1 were highly expressed. Furthermore, by electrophysiology, we detected a volume-activated anion channel on human osteoclasts. Screening 50 different human tissues showed a broad expression for CLIC1 and a restricted immunoreactivity for ClC-7, appearing mainly in osteoclasts, ovaries, appendix, and Purkinje cells. This highly selective distribution predicts that inhibition of ClC-7 should specifically target osteoclasts in vivo. We suggest that NS3736 is inhibiting ClC-7, leading to a bone-specific effect in vivo.
In conclusion, we show for the first time that chloride channel inhibitors can be used for prevention of ovariectomy-induced bone loss without impeding bone formation. We speculate that the coupling of bone resorption to bone formation is linked to the acidification of the resorption lacunae, thereby enabling compounds that directly interfere with this process to be able to positive uncouple this process resulting in a net bone gain.
氯离子通道活性对于破骨细胞功能至关重要。因此,抑制破骨细胞氯离子通道应能防止骨吸收。相应地,我们对一种氯离子通道抑制剂进行了骨转换测试,发现它能抑制骨吸收而不影响骨形成。本研究表明,氯离子通道抑制剂在治疗骨质疏松症方面极具前景。
氯离子通道抑制剂NS3736在体外可阻断破骨细胞酸化和吸收,IC50值为30微摩尔。在大鼠卵巢切除骨质疏松模型中进行测试时,术后6周每天口服30毫克/千克可使骨强度和骨密度提高约50%。最有趣的是,通过骨钙素、矿物质沉积率和矿化表面指数评估的骨形成并未受到抑制。
对人破骨细胞中氯离子通道的分析显示,ClC-7和CLIC1高度表达。此外,通过电生理学方法,我们在人破骨细胞上检测到一种容积激活阴离子通道。对50种不同人体组织进行筛查显示,CLIC1广泛表达,而ClC-7免疫反应性受限,主要出现在破骨细胞、卵巢、阑尾和浦肯野细胞中。这种高度选择性分布预示,抑制ClC-7在体内应能特异性作用于破骨细胞。我们认为NS3736正在抑制ClC-7,从而在体内产生骨特异性作用。
总之,我们首次表明,氯离子通道抑制剂可用于预防卵巢切除引起的骨质流失而不阻碍骨形成。我们推测,骨吸收与骨形成的偶联与吸收陷窝的酸化有关,从而使直接干扰这一过程的化合物能够正向解偶联这一过程,导致净骨量增加。